http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2756489-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_114e4acba47320b61a9897f0c7ddf884
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2800-28
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-44
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-365
filingDate 1996-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1998-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber FR-2756489-A1
titleOfInvention COMPOSITIONS FOR THE TREATMENT OF HYPERKERATOSIS
abstract The invention relates to the production of anti-hyperkeratotic compositions characterized in that they contain, as active elements, either individually or in admixture, organic acids hydroxylated in alpha, partially neutralized by a basic amino acid, such as lysine or l arginine or silk acylamino acids comprising serine which is the only linear amino acid comprising an alpha hydroxyl.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010043346-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3965724-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1104671-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0139734-A1
priorityDate 1996-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0413528-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5420106-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2520613-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S588007-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407364031
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450203074
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID111433
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432502108
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483812
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86667330
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86600973
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71077
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451726608
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415814663
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID757
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397365
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154383695

Total number of triples: 42.